Abstract
Heat shock proteins (HSPs) are vital in the progression of cancer, aiding in the survival, proliferation, and metastasis of tumor cells. The overexpression of particular HSPs, such as HSP70 and HSP27, is often found in various malignancies, including lung, breast, and prostate cancers, and correlates with poor prognosis and enhanced resistance to chemotherapy. These proteins stabilize oncogenic proteins, inhibit apoptosis, and modulate the tumor microenvironment, contributing to cancer aggressiveness. Recent studies highlight the potential of HSPs as biomarkers for predicting cancer prognosis and treatment response. Targeting HSPs with specific inhibitors, notably HSP90 inhibitors, has come forth as a viable therapeutic approach to disrupt cancer-related processes and enhance the effectiveness of chemotherapy treatments. Targeting HSPs offers a multi-targeted approach, as these chaperones stabilize multiple oncogenic proteins simultaneously. Overall, this review aims to provide a comprehensive overview of HSPs in cancer, focusing on their role in tumor progression, their clinical implications as biomarkers and therapeutic targets, and the latest developments in HSP-targeted therapies.
EUVIMED